2018/07/12 by W. Virgil Brown · 1 citation
Medicine · Biochemistry, Genetics and Molecular Biology · #Lipoproteins and Cardiovascular Health #Diabetes, Cardiovascular Risks, and Lipoproteins #Cancer, Lipids, and Metabolism
paper · doi:10.1002/cpt.1127
openalex publication_date 2018/07/12 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/15
Genetic, metabolic, and lifestyle modifications can cause elevations of lipoproteins that contribute to atherosclerotic lesions over time. In the modern world with life extension from many improvements in medicine and public health, most humans live long enough to develop atherosclerosis with concentrations of blood plasma lipoproteins that are very common. Familial abnormalities are prevalent and provide additional challenges in identifying unhealthy but treatable values of low-density (LDL) and very low-density lipoproteins (VLDL). Multiple community studies and clinical trials have provided guidance on selecting targets and new tools that make possible effective goals of treatment. Lipid-lowering drugs are making it possible to achieve those goals and place responsibility on physicians to master the art of preventing atherosclerotic events. Lipoprotein management remains a very focused effort and requires an artful individualized approach for each patient. Few skills are more important for healthcare providers in primary care and cardiovascular medicine.